Oxford Immunotec's T-SPOT®.TB Test Included in the World Health Organization's First-Ever Essential Diagnostics List
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 21, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that the Company's T-SPOT.TB test for tuberculosis (TB) infection has been included in the World Health Organization (WHO) Model List of Essential In Vitro Diagnostics (EDL) - First Edition.
The EDL includes the 113 most important tests recommended by WHO for use at various levels of the health care system. These essential diagnostics satisfy the priority health care needs of the population and were selected with due regard to disease prevalence and public health relevance, evidence of efficacy and accuracy, and comparative cost-effectiveness. 58 of the tests listed are for the detection and diagnosis of a wide range of common conditions, providing an essential package that can form the basis for screening and management of patients. The remaining 55 tests are designed for the detection, diagnosis, and monitoring of WHO key disease areas, for which there is high quality evidence - HIV, tuberculosis (TB), malaria, hepatitis B and C, syphilis and human papilloma virus. Included in the list were interferon-gamma release assays, of which Oxford Immunotec's T-SPOT.TB test is one of two available globally.
"Despite steady progress in reducing the burden of tuberculosis in recent decades, TB remains a major global health problem and one of the top 10 causes of death worldwide," said Dr. Richard Wenstrup, Chief Medical Officer of Oxford Immunotec. "As acknowledged in the February 2018 publication of new WHO guidelines1, the identification and management of LTBI in people with a high risk of developing active TB is a critical component of the WHO End TB Strategy. We applaud the inclusion of IGRAs in the WHO's EDL and are pleased to see further recognition of the important role IGRAs will play in the global fight against TB."
1 Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company's first product is the T-SPOT.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.
This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, and intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.
Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.
For Media and Investor Inquiries:
Head of Strategy and Investor Relations
Tel: +1 (508) 556-1377
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
FROM CUTE TO CONFIDENT: MARY KAY INC. TALKS PINK AT THE MUSEUM AT FIT13.12.2018 14:00 | Pressemelding
Mary Kay Inc. and The Museum at The Fashion Institute of Technology Partner for a Pink-Centric Panel Discussion in Conjunction with Special Exhibition ‘Pink: The History of a Punk, Pretty, Powerful Color’ NEW YORK, N.Y., Dec. 13, 2018 (GLOBE NEWSWIRE) -- From pink makeup compacts to the iconic pink Cadillac, global beauty brand Mary Kay has been synonymous with the color pink for more than five decades. On December 13, 2018, Mary Kay will partner with The Museum at FIT (MFIT) to host a scholarly panel discussion, ‘Powerful Pink: From Cute to Confident,’ at the Katie Murphy Amphitheatre on the New York City FIT campus. Panelists include Luis Casco, Mary Kay Global Beauty Ambassador and celebrity makeup artist; Kate Greene, Vice President of Communications and Creative Direction at Givaudan and Karen Young, FIT adjunct professor and founder of The Young Group. The panel discussion will be moderated by Sheryl Adkins-Green, Chief Marketing Officer for Mary Kay Inc. The scholarly panel disc
XBiotech Announces Publication of Post-Hoc Analysis for Phase III Colorectal Cancer Study13.12.2018 14:00 | Pressemelding
Biomarkers Predict Significantly Higher Rates of Treatment Response to Bermekimab in Advanced Cancer Patients AUSTIN, Texas, Dec. 13, 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today the publication of findings on key biomarker analysis of colorectal cancer patients treated with bermekimab in its European Phase III study. The manuscript, entitled, “Interleukin-1 Receptor Antagonist (IL-1ra) Levels Predict Favorable Outcome after Bermekimab, a First-in-Class True Human Interleukin-1α Antibody, in a Phase III Randomized Study of Advanced Colorectal Cancer”, has been published online in the journal OncoImmunology. The findings report that patients with relatively low levels of IL-1ra or IL-6 were more likely to respond to bermekimab therapy and achieve the study’s primary endpoint. The study’s primary endpoint measured a combination of physical symptoms—pain, fatigue, anorexia and muscle wasting—which tend to worsen with advanced cancer, to assess whether these sympto
DoubleVerify Launches Brand Safety and Suitability Verification Across YouTube, Extending Quality Coverage for Global Brands13.12.2018 14:00 | Pressemelding
DV expands its partnership with YouTube to identify off-brand content, enabling measurement of Authentic ImpressionⓇ delivery NEW YORK, Dec. 13, 2018 (GLOBE NEWSWIRE) -- DoubleVerify ("DV"), the leading independent provider of marketing measurement software and analytics, today announced an expanded partnership with YouTube to deliver brand safety and suitability measurement for campaigns run on the platform. The partnership drives greater campaign transparency and unlocks potential performance for advertisers wishing to avoid unsuitable content or categories of lesser relevance to the brand. “We are excited to enter a new phase of partnership with YouTube,” said Wayne Gattinella, CEO of DoubleVerify. “Today, brand suitability is a core advertiser expectation – across all media types and buying platforms. With our expanded partnership, DoubleVerify is ensuring brand suitability on the world’s leading online video platform.” YouTube advertisers will now benefit from DV’s best-in-class B
BST wins second contract to build cars for the growing high-speed rail network13.12.2018 12:30 | Pressemelding
Second order of new Chinese standard high-speed train cars demonstrates Bombardier joint venture’s competitiveness and ability to deliver proven high-speed mobility solutions Bombardier has been increasingly active in developing China’s advanced railway networks with multiple high-speed railcar orders BERLIN, Dec. 13, 2018 (GLOBE NEWSWIRE) -- Bombardier Sifang (Qingdao) Transportation Ltd. (BST), a joint venture of global mobility solution provider Bombardier Transportation, announced today that it has won a second contract this year to support China’s evolving high-speed rail network. The new contract, awarded by China Railway Corp. (CRC), is to supply 168 CR400AF new Chinese standard high-speed train cars and is valued at approximately 3.1 billion CNY ($453 million US, 399 million euro). Bombardier Transportation owns 50% of the shares in BST, which is consolidated by Bombardier Transportation’s partner CRRC Sifang Co., Ltd. The 168 cars will be configured into fifteen 8-car trainset
GridGain® Professional Edition 2.7 Introduces TensorFlow Integration, Enhanced Usability, Transparent Data Encryption at Rest13.12.2018 09:00 | Pressemelding
Native TensorFlow Integration Enables Seamless Deep Learning on Data in GridGain FOSTER CITY, Calif., Dec. 13, 2018 (GLOBE NEWSWIRE) -- GridGain Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite™, today announced the immediate availability of GridGain Professional Edition 2.7, a fully supported version of Apache Ignite 2.7. GridGain Professional Edition 2.7 introduces TensorFlow™ integration for enhanced training of deep learning (DL) models. GridGain Professional Edition 2.7 also provides enhanced usability, including expanded support for thin clients, as well as Transparent Data Encryption at rest to improve security. Together, the features make it easier to use the GridGain In-Memory Computing Platform for more use cases, such as for achieving the speed and scalability required for implementing real-time continuous learning for digital transformation and omnichannel customer experience initiatives. TensorFlow Integration for High Performance
Feelunique–Europe’s largest online beauty retailer–expands partnership with Moovweb13.12.2018 03:28 | Pressemelding
Feelunique will introduce a new App-like Mobile Site powered by Moovweb SAN FRANCISCO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Feelunique, Europe’s largest online beauty retailer, announced today that it has expanded its long-standing partnership with Moovweb, by building an innovative Progressive Web App (PWA) with The Moovweb Experience Delivery Network (XDN) that powers modern mobile experiences for the world’s leading brands. The company’s new eCommerce experience will allow shoppers to browse, checkout and purchase items as fast as an app in their mobile browser without requiring a mobile app download. Powered by The Moovweb XDN, the new web experience will dramatically speed up mobile shopping–search, browsing and buying products–leveraging PWA technology. Now that page load speed is a key factor for SEO thanks to new rules that rank which mobile sites appear first on Google, best-in-class eCommerce brands are utilizing PWA technology. With PWAs, follow-up pages are pre-cached giving t
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom